Primary brain tumours in adults, Lancet, vol.379, issue.11, pp.61346-61355, 2012. ,
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathologica, vol.131, issue.6, pp.803-820, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-996, 2005. ,
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.70025-70032, 2009. ,
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma, British Journal of Cancer, vol.64, issue.4, pp.769-774, 1991. ,
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era, Neuro-Oncology, vol.15, issue.1, pp.104-111, 2012. ,
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu, Blood, vol.101, issue.2, pp.703-705, 2003. ,
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells, Oncogene, vol.23, issue.54, pp.8766-8776, 2004. ,
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity, Molecular Cancer Therapeutics, vol.13, issue.2, pp.364-374, 2013. ,
Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer, Clinical Cancer Research, vol.22, issue.10, pp.2596-2596, 2016. ,
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer, Clinical Cancer Research, vol.22, issue.5, pp.1095-1102, 2015. ,
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer, Gynecologic Oncology, vol.156, issue.1, pp.23-31, 2020. ,
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer, Investigational New Drugs, vol.38, issue.4, pp.1145-1155, 2019. ,
Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma, International Journal of Radiation Oncology*Biology*Physics, vol.81, issue.3, pp.623-630, 2011. ,
Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities, Biometrics, vol.56, issue.4, pp.1177-1182, 2000. ,
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, Journal of Clinical Oncology, vol.28, issue.11, pp.1963-1972, 2010. ,
O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions, International Journal of Molecular Sciences, vol.13, issue.6, pp.6983-6994, 2012. ,
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients, European Journal of Cancer, vol.49, issue.2, pp.360-368, 2013. ,
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.27, issue.23, pp.3861-3867, 2009. ,
Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas, Journal of Korean Medical Science, vol.21, issue.4, p.739, 2006. ,
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial, Journal of Clinical Oncology, vol.29, issue.22, pp.3050-3055, 2011. ,
Temozolomide-related idiosyncratic and other uncommon toxicities, Anti-Cancer Drugs, vol.23, issue.10, pp.1099-1106, 2012. ,
Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation, Radiation Oncology, vol.6, issue.1, p.141, 2011. ,
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, The Lancet Oncology, vol.13, issue.7, pp.707-715, 2012. ,
Fatal Reactivation of Hepatitis B with Temozolomide, New England Journal of Medicine, vol.356, issue.15, pp.1591-1592, 2007. ,
Hepatic encephalopathy after treatment with temozolomide, Journal of Neuro-Oncology, vol.103, issue.1, pp.163-166, 2010. ,
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system, Neuro-Oncology, vol.14, issue.5, pp.541-546, 2012. ,
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide, Acta Neurologica Belgica, vol.113, issue.4, pp.527-530, 2013. ,
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells, Oncogene, vol.23, issue.54, pp.8766-8776, 2004. ,
Inhibition of p38? MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo, Leukemia, vol.20, issue.6, pp.1017-1027, 2006. ,
Inhibition of p38 Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma, Cancer Research, vol.67, issue.10, pp.4572-4577, 2007. ,
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth, British Journal of Haematology, vol.136, issue.3, pp.414-423, 2007. ,
BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells, PLoS ONE, vol.8, issue.1, p.e54181, 2013. ,
The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer, Cancer Biology & Therapy, vol.17, issue.5, pp.566-576, 2016. ,
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization, EBioMedicine, vol.28, pp.51-61, 2018. ,
Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn?s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Gastroenterology and Hepatology, vol.4, issue.3, pp.325-334, 2006. ,
Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome, Leukemia, vol.27, issue.4, pp.977-980, 2012. ,
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial, The Lancet, vol.384, pp.60417-60424, 2014. ,